Foghorn Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
Foghorn Therapeutics Inc. filed a Form 8-K under Item 8.01 to report a change in its senior leadership. The report is dated August 3, 2023, while the disclosed press release and filing signature are dated August 8, 2023. No quarterly or annual financial results are included.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, operating margin, debt, cash balance, liquidity, or other financial metrics.
Material Changes
- Samuel Agresta, M.D., will step down as Chief Medical Officer effective September 11, 2023.
- Following his resignation, Dr. Agresta will serve as a consultant through early January 2024.
- Alfonso Quintás-Cardama, M.D., has been appointed Chief Medical Officer effective September 11, 2023.
- Dr. Quintás-Cardama previously served as Chief Medical Officer of TCR 2 Therapeutics Inc. and held clinical development and oncology roles at GlaxoSmithKline, Novartis, and MD Anderson Cancer Center.
Outlook, Risks, and Unusual Items
The filing provides no financial guidance or detailed business outlook. The leadership transition could affect clinical development and operational execution, but the filing does not identify any specific expected impact, compensation terms, severance arrangements, or contingencies.
Key Facts to Verify
- Confirm the effective date of Dr. Agresta’s departure and the duration of his consulting arrangement.
- Confirm the effective appointment date and responsibilities of Dr. Quintás-Cardama.
- Review subsequent filings and company disclosures for any changes to clinical programs, development timelines, or management guidance following the transition.
- Review the company’s periodic financial filings separately for cash runway, operating losses, liquidity, and financing needs, as these data are absent from this 8-K.